BCR-ABL Ratios in Patients with CML

Video

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses BCR-ABL Ratios in patients with chronic-phase chronic myeloid leukemia

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses BCR-ABL Ratios in patients with chronic-phase chronic myeloid leukemia (CML).

Clinical Pearls:

  • CML patients who are taking ABL-TKI inhibitors and do not reach a BCR-ABL ratio of <10% at 3 months of treatment have a worse prognosis
  • Data from an Australian study also found that patients who did not reach this milestone had a worse progression-free and overall survival
  • Patients in this study who remained on imatinib and achieved a 6-month goal of a BCR-ABL ratio of <1% had a progression-free and overall survival similar to patients who achieved a BCR-ABL ratio of <10% at 3 months
Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content